RE:RE:Results clear on some things, not on others..I’m not a Dr. The "triplet therapy" (Cohort 3) involving the addition of an immune checkpoint inhibitor resulted in a 70.6% disease control rate at 16 weeks versus a 46.7% control rate for the placebo of paclitaxel alone (Cohort 1). And this result occured in a heavily pre-treated group of metastatic breast cancer patients.